Part 5/9:
Next, Matt Argersinger introduces Illumina, a giant in the genomics sequencing industry, occupying a commanding position with applications spanning biotech research, cancer diagnostics, and large hospital systems. Despite a recent 40% decline from its peak, Illumina remains dominant.
Argersinger advocates for the company's compelling razor-and-blades business model—selling high-demand sequencing equipment that fuels recurring consumable revenues. He considers Illumina a prime way for investors to gain exposure to groundbreaking biotech advancements without directly investing in volatile biotech stocks.